Detalhe da pesquisa
1.
Sodium-Glucose Cotransporter-2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-Analysis.
Circulation
; 149(23): 1789-1801, 2024 Jun 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38583093
2.
SGLT2 Inhibitors: The Sweet Success for Kidneys.
Annu Rev Med
; 74: 369-384, 2023 01 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-36706745
3.
Effects of Empagliflozin on Fluid Overload, Weight, and Blood Pressure in CKD.
J Am Soc Nephrol
; 35(2): 202-215, 2024 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38082486
4.
Chronic kidney disease in type 1 diabetes: translation of novel type 2 diabetes therapeutics to individuals with type 1 diabetes.
Diabetologia
; 67(1): 3-18, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37801140
5.
Evaluation of glomerular hemodynamic changes by sodium-glucose-transporter 2 inhibition in type 2 diabetic rats using in vivo imaging.
Kidney Int
; 2024 May 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-38801992
6.
Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease.
N Engl J Med
; 384(2): 129-139, 2021 01 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-33200891
7.
Virtual Pharmacy: An Integrated Collaborative Redesign Targeting Medication-Related Problems in Patients with Chronic Kidney Disease.
Am J Nephrol
; 55(2): 206-213, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-37939689
8.
Proximal versus distal diuretics in congestive heart failure.
Nephrol Dial Transplant
; 2024 Feb 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38425090
9.
Volenrelaxin (LY3540378) increases Renal Plasma Flow: A Randomized Phase 1 Trial.
Nephrol Dial Transplant
; 2024 May 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38782726
10.
Design and baseline characteristics of the Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease (FIND-CKD) randomized trial.
Nephrol Dial Transplant
; 2024 Jun 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-38858818
11.
An update review of post-transplant diabetes mellitus: Concept, risk factors, clinical implications and management.
Diabetes Obes Metab
; 26(7): 2531-2545, 2024 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-38558257
12.
Renal and Vascular Effects of Combined SGLT2 and Angiotensin-Converting Enzyme Inhibition.
Circulation
; 146(6): 450-462, 2022 08 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35862082
13.
Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared with placebo.
Kidney Int
; 103(4): 772-781, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36738891
14.
Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes.
N Engl J Med
; 383(15): 1425-1435, 2020 10 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32966714
15.
Novel Therapies in Diabetic Kidney Disease and Risk of Hyperkalemia: A Review of the Evidence From Clinical Trials.
Am J Kidney Dis
; 82(6): 737-742, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37517546
16.
Efficacy and safety of sotagliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease.
Diabetes Obes Metab
; 25(6): 1646-1657, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36782093
17.
Safety, tolerability, pharmacodynamics and pharmacokinetics of the soluble guanylyl cyclase activator BI 685509 in patients with diabetic kidney disease: A randomized trial.
Diabetes Obes Metab
; 25(8): 2218-2226, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37232058
18.
Cardiorenal outcomes by indices of liver steatosis and fibrosis in individuals with type 2 diabetes and atherosclerotic cardiovascular disease: Analyses from VERTIS CV, a randomized trial of the sodium-glucose cotransporter-2 inhibitor ertugliflozin.
Diabetes Obes Metab
; 25(3): 758-766, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36394384
19.
Potential Use of SGLT-2 Inhibitors in Obstructive Sleep Apnea: A new treatment on the horizon.
Sleep Breath
; 27(1): 77-89, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35378662
20.
Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial.
Diabetologia
; 65(7): 1085-1097, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35445820